Pure Global AI
NCT06278493Completed

A Clinical Study of AL2846 Capsule Combined With Gemzar Injection in the Treatment of Advanced Pancreatic Cancer

A Phase I/IIa Clinical Trial AL2846 Capsule Combined With Gemzar Injection in the Treatment of Advanced Pancreatic Cancer.
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Phase 1/2ClinicalTrials.govdrug
Verified
Study focus
Disease/Condition
Pancreatic Cancer
Drug/Device/Intervention
AL2846 capsules
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Location
Tianjin, China
Timeline & enrollment
Phase
Phase 1/2
Start date
Aug 23, 2018
End date
May 01, 2023
Enrollment
34 participants
Primary outcome

Dose limiting toxicity (DLT),Maximum tolerated dose (MTD)

Summary

This is a clinical study to observe the tolerance and primary efficacy of AL2846 capsules
 combined with Gemzar injection in patients with pancreatic cancer, and to determine the
 recommended dosage and administration method for subsequent clinical studies.

ICD-10 classifications
Malignant neoplasm of pancreasMalignant neoplasm: Pancreas, unspecifiedMalignant neoplasm: Head of pancreasMalignant neoplasm: Tail of pancreasMalignant neoplasm: Other parts of pancreas
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06278493
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06278493 through Pure Global AI's free database. This Phase 1/2 trial is sponsored by Chia Tai Tianqing Pharmaceutical Group Co., Ltd. and is currently Completed. The study focuses on Pancreatic Cancer. Target enrollment is 34 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.